{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T07:30:44Z","timestamp":1648971044497},"reference-count":14,"publisher":"Georg Thieme Verlag KG","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Klassifikation 2020\u2002Die neuen ACR\/EULAR-Klassifikationskriterien f\u00fcr den systemischen Lupus erythematodes (SLE) stellen einen wichtigen Beitrag zur Optimierung klinischer Studien und eine Hilfestellung zur Diagnostik dar. So kann ein SLE erst als solcher klassifiziert werden, wenn antinukle\u00e4re Antik\u00f6rper (ANA) ab einer Titerh\u00f6he von 1:80 unabh\u00e4ngig vom Fluoreszenzmuster nachgewiesen werden. Sind ANA nachgewiesen, erhalten Lupus-spezifische Symptome und serologische Auff\u00e4lligkeiten eine unterschiedliche Wichtung f\u00fcr die Klassifikation.<\/jats:p><jats:p>\n          Therapie 2020\u2002Mit der \u00dcberarbeitung der EULAR-Empfehlungen zum Management des SLE sowie der Lupusnephritis und des Antiphospholipid-Syndroms stehen nun wichtige neue Therapieprinzipien zur Verf\u00fcgung. So sollte jede Lupus-Therapie ganz im Sinne eines Treat-to-Target-Ansatzes das Ziel der Remission verfolgen. Dies dient der Sicherung des Langzeit\u00fcberlebens, der Reduktion von Schaden sowie der Verbesserung von Lebensqualit\u00e4t. Erreicht werden diese Ziele durch konsequente Therapie auf Basis einer regelm\u00e4\u00dfigen Evaluation der Krankheitsaktivit\u00e4t. Alle Patienten sollen bei Abwesenheit von Kontraindikationen Antimalariamittel erhalten. Bei unzureichendem Ansprechen auf Antimalariamittel bzw. organgef\u00e4hrdende Manifestationen werden Steroidpulse (\u00fcber wenige Tage) sowie der fr\u00fchzeitige Einsatz von Immunsuppressiva (IM) und Biologika wie Belimumab und Rituximab (off-label) empfohlen.<\/jats:p>","DOI":"10.1055\/a-1037-5326","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T22:43:42Z","timestamp":1594161822000},"page":"1179-1183","source":"Crossref","is-referenced-by-count":0,"title":["Lupus 2020"],"prefix":"10.1055","volume":"145","author":[{"given":"Johanna","family":"Mucke","sequence":"additional","affiliation":[{"name":"Poliklinik f\u00fcr Rheumatologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[{"name":"Poliklinik f\u00fcr Rheumatologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"M Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/acr.23292","article-title":"Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data","volume":"70","author":"N Leuchten","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"A Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/annrheumdis-2018-214043","article-title":"Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis","volume":"78","author":"M B Urowitz","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/0961203310395802","article-title":"Assessment of flares in lupus patients enrolled in a phase II\/III study of rituximab (EXPLORER)","volume":"20","author":"J Merrill","year":"2011","journal-title":"Lupus"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"B H Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"S 10","key":"ref8","first-page":"Abstract 939","article-title":"A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis [abstract]","volume":"71","author":"R Furie","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"I M Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"M G Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"V Pengo","year":"2018","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"E F Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"R A Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"D J Wallace","year":"2018","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"R F van Vollenhoven","year":"2018","journal-title":"Lancet"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1037-5326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T22:32:20Z","timestamp":1597357940000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1037-5326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":14,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2020,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1037-5326","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}